US-based Flagship Pioneering has launched a genomics medicine company, Omega Therapeutics, to develop drugs that will leverage the human genome to cure or treat various diseases.

The epigenetic drugs regulate genomic expression without impacting nucleic acid sequences.

Omega Therapeutics was originally founded in 2017, developing a platform to accurately control the human genome’s Insulated Genomic Domains (IGDs), the fundamental regulator, or GenomStats.

Based on the mechanism, the company will engineer genomic modulators, Omega Controllers, for precise tuning of genomic activity to desired therapeutic levels to tackle the biological cause of disease.

Flagship Pioneering general partner David Berry said: “Omega’s proprietary platform technology allows us to develop therapeutics for disease control and potentially impact the way we treat and manage a broad range of illnesses.

“In addition to our own capabilities for therapeutic development, our technology also presents the opportunity to partner and optimise other targeted in vivo and ex vivo therapeutics to enhance their ability to treat disease and further help a wide range of patient populations with significant unmet needs.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Some diseases occur due to changes in gene expression or IGD structure. Omega Controllers regulate the GenomStat and in turn, single or multi-gene expressions to levels required for the treatment or cure of disease.

Omega Therapeutics also plans to optimise existing therapies across multiple therapeutic areas, such as rare genetic diseases, inflammation, metabolic diseases, immunology and oncology.

Currently, the company is working towards early-stage discovery programmes and will further boost its platform to address conditions related to genomic malfunction or dysregulation.

Macrolide Pharmaceuticals’ former president and CEO Mahesh Karande has been selected to serve as the company’s president, CEO and member of the board of directors.